logo
July's ‘Buck Moon': When to see the full moon and how it gets its name

July's ‘Buck Moon': When to see the full moon and how it gets its name

Yahoo4 days ago
TAMPA, Fla. (WFLA) — Head outside after the sun sets Thursday and you might catch a glimpse of a spectacular sight rising in the night sky.
The full 'Buck Moon' will rise on Thursday, July 10, reaching peak illumination at 4:36 p.m. EDT, according to the Farmer's Almanac.
Sea turtle photobombs family photoshoot to lay eggs
The moon will be below the horizon at that time but should be visible in the southeastern sky just after sunset.
This year will be particularly special due to a phenomenon known as a 'Major Lunar Standstill,' according to space.com.
The phenomenon occurs once every 18.6 years when the sun's gravity affects the moon's orbit and makes it appear especially high or low in the sky, depending on the time of year.
It will be low this year and may even take on a golden or reddish hue due to rays of light having to travel father through Earth's atmosphere.
So why is it called the Buck Moon? Like many moon names, it is derived from North American tribes who took notice of things happening in the natural world around them.
Male deer, or bucks, shed and regrow their antlers each year, and July's full moon rises at the same time the animals' antlers are in full growth mode, according to the Farmer's Almanac.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Business Wire

time10 hours ago

  • Business Wire

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period. 'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University. Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.' The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period. LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027. The presentation and posters are available on the ' Presentations ' tab of the Amylyx website. Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, The webcast will be archived and available for replay for 90 days following the event. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About the LUCIDITY Trial LUCIDITY (NCT06747468) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit and follow us on LinkedIn and X. For investors, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Volcanoes in multiple states have been rumbling. What's going on?
Volcanoes in multiple states have been rumbling. What's going on?

USA Today

time21 hours ago

  • USA Today

Volcanoes in multiple states have been rumbling. What's going on?

Volcanoes in Alaska, Washington state, Oregon and Hawaii have recently been rumbling and even spewing lava, enough to spark a swarm of news stories. But despite the jolts and temblors, geologists say there's no cause for alarm. "Volcanoes can be unpredictable and there's always chance that something bad will happen, but these recent seismic events along the Pacific Ring of Fire from Alaska to Washington to offshore Oregon are probably not directly related to each other," said Natalia Ruppert, a seismologist with the U.S. Geological Survey's Earthquake Science Center in Seattle. "This is what volcanoes do," she said. "They come to life for a while, sometimes the earthquake activity leads to an eruption and sometimes it doesn't." Most of the U.S. volcanoes that have been making themselves known since spring woke up a bit, shook themselves off and then fell back into slumber. Two, one in Hawaii and one in Alaska, are in the midst of active and ongoing – but relatively small and non-threatening – eruptions. While it all might seem ominous, it isn't. It's simply part of life on a dynamic, seismically active planet. There's no direct connection between any of these, said Ruppert. "The distance between these (seismic) activity centers is thousands of miles." Recent US volcanic activity While volcanoes have always been a part of the West Coast's geography, it might seem that this is an especially busy time for these mountains caused by fissures in the Earth's crust that go down to the mantle below. But seismologists and volcanologists are keeping a careful eye on them, said Ruppert. "This is why the federal government funds earthquake and volcano monitoring efforts through the Department of the Interior and USGS." Consider these recent events: The volcanoes are located along what's known as the Ring of Fire, a 25,000-mile long, horseshoe-shaped string of volcanoes and seismically active areas that stretches from the southern tip of South America, up along the West coast of the United States, across the coast of Alaska, down through Japan all the way to New Zealand. It's created by the Pacific plate sinking below the North American plate and is the most seismically and volcanically active zone in the world, according to the U.S. Geological Survey. Eruptions in Hawaii Far to the west in Hawaii, Mt. Kilauea continues to erupt, though as of July 11 it has not been exhibiting the massive fountains of lava that had been taking place earlier in the month. On July 9, USGS said the most recent eruption had ended. Hawaii's volcanoes are not part of the Ring of Fire. The island chain was (and is still being) formed by a volcanic hot spot that has so far created 15 different volcanoes that stretch 3,800 miles across the Pacific. In Hawaii's case, the volcanoes are the result of a heat source deep within the Earth's mantle. The plume of magma coming from that hot spot in the ocean floor remains stationary as the Pacific Plate slowly – 2 to 4 inches a year – moves over top of it. This is why Hawaii's oldest volcanoes, on Kauai, are 5.5 million years old while the newest, on the Big Island, are only 700,000 years old and still growing.

The July full moon will create an optical illusion. Peak time to see the 'Buck moon' in RI
The July full moon will create an optical illusion. Peak time to see the 'Buck moon' in RI

Yahoo

time2 days ago

  • Yahoo

The July full moon will create an optical illusion. Peak time to see the 'Buck moon' in RI

July's full moon, known as the Buck Moon, is rising this week – with a trick. On July 10, July's full moon will be at its peak at 4:37 p.m. ET, according to the Old Farmer's Almanac. It will be below the horizon when it reaches its peak, but you can face southeast to watch the moon rise following sunset. The full moon will be visible from July 9 to July 10, according to NASA. The trick will be when it rises. The Earth is currently just about at its farthest point from the sun in its orbit, according to Live Science, which means the moon is also at its farthest point. This creates an interesting moon rise, where is will appear low in the sky, giving it an unnaturally large appearance known as the moon illusion. "Photographs prove that the moon is the same width near the horizon as when it's high in the sky, but that's not what we perceive with our eyes," NASA says. "Thus, it's an illusion rooted in the way our brains process visual information. Even though we've been observing it for thousands of years, there's still not a satisfying scientific explanation for exactly why we see it." The weather is looking less than ideal for watching a moonrise. AccuWeather is forecasting clouds and rain on July 9 and clouds and thunderstorms on July 10 in Providence. The Buck Moon, a Native American term, is called as such because "the antlers of male deer (bucks) are in full-growth mode at this time," according to the Farmer's Almanac. "Bucks shed and regrow their antlers each year, producing a larger and more impressive set as the years go by." According to the Farmer's Almanac, they include: Feather Moulting Moon (Cree) Salmon Moon, (Tlingit) Berry Moon (Anishinaabe) When the Chokecherries are Ripe (Dakota) Month of the Ripe Corn Moon (Cherokee) Raspberry Moon (Algonquin, Ojibwe) Thunder Moon (Western Abenaki) Halfway Summer Moon (Anishinaabe) A full moon can be seen clearly with the naked eye. But in a past interview with USA Today Network, Tim Brothers, Massachusetts Institute of Technology technical Instructor and observatory manager, said with any case of stargazing, it's much better if you're using a good telescope or a pair of binoculars. According to Time and Date, they include: Sturgeon Moon: Aug. 9, 2025 Corn Moon: Sept. 7, 2025 Harvest Moon: Oct. 6, 2025 Beaver Moon: Nov. 5, 2025 Cold Moon: Dec. 4, 2025 The USA Today Network contributed to this report. This article originally appeared on The Providence Journal: July full moon will create 'moon illusion.' When to see it in RI

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store